Category: Discrimination

Weight discrimination as a matter of record: the laws that exist and the ones that do not, court rulings, coverage decisions, and the studies behind the claims. Who writes these rules, how they are built, and who they leave out, at the doctor’s office, at work and in the statute book.

  • What Patients Expect From Clinicians, and What Newly Qualified Clinicians Say They Were Taught

    What Patients Expect From Clinicians, and What Newly Qualified Clinicians Say They Were Taught

    A new qualitative study sets two groups of interviews side by side: adults with experience of obesity treatment, and clinicians who qualified within the last two years. Both groups say obesity is complex and should be discussed sensitively. The paper’s finding is that the agreement thins out when it comes to what a clinician actually does in the room. This article reports how the study was built and what it can and cannot show. It reports the paper’s content, evaluates no treatment and recommends none.

    The paper is “Patient expectations and healthcare professional education in obesity care: A comparative qualitative study” by Tak Ying Louise Ko, Francisca Contreras, Carel W. Le Roux and Werd Al-Najim. It appeared in Obesity Pillars, volume 20, article 100337 (doi 10.1016/j.obpill.2026.100337), open access under CC BY 4.0. The Crossref record was created on 28 September 2026, which is also the first publication date in Europe PMC. The print date differs between the two databases (December 2026 in Crossref, September 2026 in Europe PMC), so we cite the article number and not an issue. Fatosphere read the full text and Table 1. The supplementary files (interview guides, reporting checklist) and the graphical abstract were not read.

    What the study is

    It is a secondary analysis. No one was interviewed for it. The authors went back to the full transcripts of two earlier interview studies and asked a new question: does the university education that newly qualified clinicians report match the capabilities that patients say they expect?

    The first dataset holds 20 adults with current or previous experience of obesity treatment, interviewed between October and December 2024 about their expectations of consultations. The second holds 21 newly qualified health professionals who graduated within the previous two years, interviewed between November 2024 and May 2025 about their obesity education and how prepared they felt. Of the 21, 16 were from medicine, two from physiotherapy, and one each from occupational therapy, dietetics and nursing.

    The two groups were recruited separately and answered different interview guides. They are not linked: no patient in the study saw any clinician in the study. The comparison is between patterns in two sets of accounts, not between pairs of people. The authors coded the datasets separately in MAXQDA, compared them, and refined four themes. Two authors (TYLK and FC) did the analysis, with the other two reviewing. The paper follows the SRQR reporting standard and states that no new sample-size decision was made, because it used every available transcript. The methods section does not name the country of the participants. Ethics approval came from the Human Research Ethics Committee of University College Dublin.

    The four themes

    The paper’s wording for each theme is a pair: where the groups agreed, and where they diverged.

    1. Beyond recognising obesity as multifactorial. Both groups said obesity has many causes. Patients expected that understanding to reduce blame, look beyond weight and BMI, and shape care around their own circumstances. Clinicians described remembering “concepts more than specifics”, and some called their knowledge “very surface level”. The reported gap is between knowing the principle and applying it to one person.

    2. Sensitivity requires more than sensitive language. Both groups saw weight as a topic that can feel judging. In patient accounts, sensitivity meant more than a polite manner: a conversation could be courteous and still reductive if the reasoning underneath stayed on individual behaviour. The authors call such sensitivity “tokenistic and superficial”. Some clinicians recalled teaching on stigma or on asking permission before raising weight, but little practice at carrying the conversation beyond its opening.

    3. Clinical orientation to treatment and care pathways. Patients described frustration when care stopped at generic diet and activity advice, and valued clinicians who knew what options existed and where to refer. Clinicians reported uneven confidence about treatment, referral and what follows when a first approach does not work, and the paper says this varied by profession and clinical exposure. We report this as the study’s content. This article does not weigh any treatment option.

    4. Fragmented education and the expectation of integrated care. Patients described care split across specialists, one participant calling it “very splintered” and wanting obesity recognised as an “overall binding condition”. Clinicians described learning about obesity piecemeal, as a risk factor or comorbidity inside other subjects, with some having seen obesity mostly as a complication and rarely as the focus of care.

    What the authors conclude

    The authors read the pattern as a gap in translation, not in topic coverage. Their abstract says education “may therefore benefit from greater integration” of obesity knowledge, communication and care pathways, “rather than solely increasing curricular content”. They add that they cannot show that fragmented teaching causes fragmented care. The parallel between the two is an observation of the study, not a tested link.

    What the study cannot show

    Patients are not a yardstick. The paper says patient expectations are not an objective measure of clinician competence, and clinician self-reports are not observations of practice. The finding is about perceived correspondence.

    Mostly doctors. 16 of 21 clinicians came from medicine, so statements about other professions rest on one to two people each.

    Patients with treatment experience. All 20 had current or previous experience of obesity treatment. The authors note they may not represent people receiving obesity care in primary or other settings.

    Questions not built for this comparison. The interviews were designed for other research questions. The authors say so, and argue that returning to the full transcripts still allowed a question neither original study could answer.

    Quotes are selected. Qualitative papers show chosen excerpts. We cannot check from the article how typical any single quote is, and we have not seen the transcripts.

    The frame and the interests

    The premise is the authors’. The paper describes obesity as a complex chronic disease with a growing range of management approaches, and treats discussion of lifestyle, medication and surgery as part of what patients can expect. We report that as their frame. It is not our finding.

    Funding and disclosures. The paper states funding from the European Commission’s Erasmus Mundus Design Measure (grant 101128158) and says it is part of the SOPHIA project, funded by the Innovative Medicines Initiative 2 Joint Undertaking, with support the paper lists as coming from EFPIA, T1D Exchange, JDRF and the Obesity Action Coalition. The disclosures state that one author serves on advisory boards of several companies, among them Novo Nordisk and Eli Lilly, and that another reports honoraria from Novo Nordisk and Boehringer Ingelheim and provides dietetic services to private obesity clinics. The authors disclose all of this. We note it because it shapes how the topic is framed.

    Language tools. The authors declare that ChatGPT was used only for grammar correction.

    Graphic: 20 patient interviews and 21 interviews with newly qualified health professionals by profession, plus the four reported themes. No people.
    Grafik: Fatosphere Editorial. Quelle: Ko et al., Obes Pillars 2026;20:100337. Gelesen am 20.10.2026.

    How it connects to our other work

    For a quantitative look at training programmes, see Does Obesity Training for Clinicians Work? What a Rapid Review Measured, and What Its Numbers Rest On. A small pilot of a one-hour course is in Weight-Inclusive Care in Primary Care.

    Source: Ko TYL, Contreras F, Le Roux CW, Al-Najim W. “Patient expectations and healthcare professional education in obesity care: A comparative qualitative study.” Obesity Pillars 2026;20:100337, doi.org/10.1016/j.obpill.2026.100337, PMC13653468. Authors, article number and license confirmed against the Crossref record. Full text read on 20 October 2026.

  • Disability Law as the Only Door: What One Perspective Paper Argues About Weight Discrimination

    Disability Law as the Only Door: What One Perspective Paper Argues About Weight Discrimination

    Where no law names body weight as a protected ground, a person who is refused a job or a service because of their size has one route left: argue that their weight is a disability. A new paper in Frontiers in Public Health says this route reaches only part of the harm, and proposes a framework and a legal design to fix it. This article reports the argument, checks what it rests on and marks where it goes beyond its evidence. It is not legal advice and it recommends no treatment.

    The paper is “Beyond forced translation: obesity, disability and the case for autonomous protection against weight discrimination” by Raúl Sampieri-Cabrera and Karen Soldatic (affiliations: National Autonomous University of Mexico, Mexico City, and Toronto Metropolitan University). It appeared in Frontiers in Public Health, volume 14, article 1937485, on 22 September 2026 (doi 10.3389/fpubh.2026.1937485), open access under CC BY 4.0. The authors report funding from PAPIIT DGAPA-UNAM and no competing interests. Their AI statement says Claude (Anthropic) and Paperpal were used for language editing only, and Connected Papers to find literature. Fatosphere read the full text. The supplementary files were not read. Our earlier digest note gave 7 October as the date; the Crossref record says 22 September.

    What kind of paper this is

    It is a perspective, a reasoned argument. It has no methods section, no systematic search and no data of its own. Everything below is the authors’ reading of law and literature, and we report it as theirs. We did not check the court rulings and statutes they cite against the originals.

    The argument

    The authors separate three things that debates often merge. Obesity, in their account, is a clinical condition, established by pathophysiology. Disability is a judgment about restricted participation that arises between a person and an environment, established by the barrier. Weight discrimination is differential treatment on the ground of body weight, established by the ground of the treatment. Because the three tests are independent, one person can meet one, two or all three. The authors count seven combinations (their Table 1) and name the response owed in each: clinical care, accommodation, or a prohibition of differential treatment.

    The center of the argument is two of those seven: weight-based exclusion where the person has no disability. Disability law reaches these only if the claimant asserts an impairment they may not have. The authors call the result a translation requirement: claimants must put an experience of weight-based exclusion into the vocabulary of functional impairment, and whatever does not fit stays unremedied. (The phrase “forced translation” is in the title; the body text describes the requirement in these terms rather than defining the phrase.)

    The comparison they draw

    For five legal systems the authors state that a claim is heard when a lasting functional limitation can be shown. For the European Union they describe Directive 2000/78/EC and the Kaltoft case: obesity is not a protected ground in itself but can be a disability when it hinders participation in working life. For the United States they describe the ADA as amended in 2008, EEOC litigation, and appeals courts holding that obesity is not an impairment unless it results from an underlying physiological disorder. They also cite the Washington Supreme Court’s Taylor ruling and local laws on height and weight. For Canada they describe weight as unlisted in the federal Human Rights Act, claims run through actual or perceived disability, and a 2025 case-law scan calling that inadequate. For the United Kingdom they cite the Equality Act 2010, which protects disability and not weight, and the Walker v SITA line. For Australia they describe the Disability Discrimination Act 1992 and the Victorian protection for physical features, which they say covers height, weight, size and shape directly.

    They also credit the disability route with real benefits: it makes part of the harm justiciable, it moves the question from moral judgment of weight to functioning and barriers, and where weight is not a protected category it is the only vehicle available.

    The risks they name

    Three risks come with routing everything through disability. Over-medicalization, meaning adiposity, disease and social participation get merged. Reinforced stigma, because a blanket reading of “incapacity” can turn into paternalism and lower expectations. And what they call a legal substitution effect: disability law absorbs claims it was not built for and leaves out harm done to people with large bodies who have no functional restriction. They add a distributional risk, since eligibility thresholds would be contested if obesity were classed as disability without functional criteria.

    Their conclusion is a hybrid. Keep disability protection for lasting functional limitation, and add weight discrimination as an autonomous prohibited ground in employment, education, health care and services. They state that obesity should not be conceptualized or regulated as a disability.

    Where it runs ahead of its evidence

    It is an argument, not a test. The seven-configuration map follows from three independent yes/no tests; with all three absent there is nothing to classify, which leaves seven. That arithmetic is ours. The mapping is a conceptual tool, and no case data show how often each configuration occurs.

    The authors say their own key evidence is thin. They write that direct evidence on whether a disability label raises or lowers weight stigma is scarce, that long-term effects of recognizing obesity under disability law are little known, and that there is no conclusive evidence on its effect on attitudes. The policy conclusion therefore rests on a legal-logic argument, not on outcome data. They also note that laws aimed at weight discrimination have not been evaluated.

    The prevalence figures are orders of magnitude. The paper cites a meta-analysis with pooled perceived weight discrimination of 19.2% (95% CI 11.7 to 29.8) for class I obesity and 41.8% (95% CI 36.9 to 46.9) above BMI 35, and itself warns that heterogeneity (I2 above 95%) means reading them as rough magnitudes.

    Legal claims are secondhand here. Every ruling and statute is described by the authors, mostly in one or two sentences, and jurisdictions inside the United States, Canada and Australia differ. The authors themselves say subnational variety complicates generalization and that part of the doctrine sits in administrative decisions and labor courts.

    A visible slip. In the implications section the paper says the WHO recommends assessing functional limitations “associated with each case of MSD”, an abbreviation that appears nowhere else in the text we read. We assume a drafting leftover and do not rely on that sentence.

    The paper uses a clinical definition we only report. The authors lean on a Lancet Diabetes & Endocrinology commission’s concept of “clinical obesity” and on the view that obesity is a chronic, relapsing disease. We report these as the authors’ premises, not as findings, and do not evaluate them or any treatment.

    Graphic: table of seven combinations of obesity, disability and weight-based exclusion, with the response owed and whether disability law alone reaches the harm. No people.
    Grafik: Fatosphere Editorial. Quelle: Sampieri-Cabrera & Soldatic, Front Public Health 2026;14:1937485. Gelesen am 18.10.2026.

    How it connects to our other work

    For the plain-language overview of weight discrimination and the law, see our guide Weight Discrimination: What It Is, What the Law Says, and What You Can Do. For a recent lab study on implicit weight bias, which is a different layer of the same problem, see Implicit Weight Bias as Missing Positivity.

    Source: Sampieri-Cabrera R, Soldatic K. “Beyond forced translation: obesity, disability and the case for autonomous protection against weight discrimination.” Frontiers in Public Health 2026;14:1937485, doi.org/10.3389/fpubh.2026.1937485, PMC13638570. Date, authors and license confirmed against the Crossref record. Full text read on 18 October 2026.

  • Implicit Weight Bias May Be a Missing Head Start, Not a Slowdown

    Implicit Weight Bias May Be a Missing Head Start, Not a Slowdown

    A research team in Freiburg, Germany, ran a quick word-classification task on 224 adults and fitted a decision-making model to the reaction times. Their finding: after seeing a computer-generated figure of “higher weight”, participants started each classification with less of a head start towards the positive answer than after a figure of “intermediate weight”. Beyond that, the data showed no difference. This article reports how the study was built, what the numbers say and where the interpretation runs ahead of the sample. It concerns prejudice research only and recommends nothing.

    The paper is “Assessing underlying processes of implicit weight bias: a diffusion model analysis” by Katja M. Pollak, Hanna Wachten, Julius Fenn, Raphael Hartmann, Constantin G. Meyer-Grant, Jana Strahler and Andrea Kiesel (University of Freiburg). It appeared in Scientific Reports, volume 16, article 27408, published online on 22 August 2026 (doi 10.1038/s41598-026-67393-1). It is open access under a CC BY 4.0 license. The authors report funding from the Deutsche Forschungsgemeinschaft and no competing interests; code and raw data are on OSF. Fatosphere read the full text. The supplementary information (word lists, trace plots, model-fit figures) was not read.

    How the studies were built

    Both studies used a reaction-time task modeled on affective priming. A picture flashes for 150 milliseconds, then a German adjective appears, and the participant presses one key for “positive” and another for “negative” as fast as possible. Participants were told to ignore the picture. The idea behind the task: if the picture carries a positive or negative association, answers are quicker when the word matches it.

    The pictures were four computer-generated body shapes per gender, made in DAZ Studio and matched to the participant’s gender: lower weight, intermediate weight, higher weight, and muscular (Study 1) or neutral (Study 2). Study 1 had 288 trials, Study 2 had 192. Weight bias was defined as the difference between the intermediate-weight and the higher-weight condition.

    Study 1 (n = 164, 124 women and 40 men, mean age 26.2, mean self-reported BMI 22.9) came from a larger online study and was recruited by convenience sampling through university mailing lists, flyers and social media. Study 2 (n = 60, 46 women and 14 men, mean age 23.7, mean BMI 22.4) used pre-intervention data from a lab study originally built to reduce weight bias. Participants needed to be adults fluent in German. In both studies the BMI came from self-reported weight and height.

    The analysis used a diffusion decision model, a standard cognitive model in which a person collects noisy evidence until one of two answers wins. It separates two things a plain reaction-time average mixes together. The drift rate describes how fast evidence for “positive” or “negative” piles up once the word is shown, and the authors read it as a change in how the stimulus is processed. The starting point describes which answer the person leans towards before the word appears, which the authors read as a judgment-related bias. The model was fitted in a Bayesian hierarchical way, and an effect counts as credible when the 95% highest density interval (HDI) of the difference excludes zero.

    What the numbers show

    The raw reaction times already show a pattern. Positive words were answered faster after the intermediate-weight figure than after the higher-weight figure: 702 versus 729 milliseconds in Study 1, 650 versus 676 in Study 2 (Table 1). Negative words took about the same time in both conditions.

    In the model, the drift-rate difference between the two conditions was not credible: the HDIs were [-0.22, 0.18] in Study 1 and [-0.34, 0.54] in Study 2. The starting point differed. In Study 1 the difference between the conditions had an HDI of [-0.06, -0.02], which excludes zero. Median starting points on a scale where 0.5 means no lean: 0.54 after intermediate-weight figures and 0.50 after higher-weight figures.

    Study 2 is weaker, and the authors say so. The two-sided HDI was [-0.06, 0.00] and included zero. Only the one-sided interval and the equal-tailed interval ([-0.06, -0.00]) excluded it, with 97.69% of the posterior below zero. Medians were 0.55 and 0.52.

    How large is the shift? A footnote simulation by the authors, run from the median estimates, gives positive answers about 20 milliseconds faster in Study 1 and 15 in Study 2, and a higher chance of a positive answer by 1.65 and 1.29 percentage points.

    The authors’ reading of the starting points against the neutral value of 0.5 is the part most worth noting. Intermediate-weight, lower-weight and muscular figures all sat credibly above 0.5. The higher-weight figure did not differ credibly from 0.5, nor from the neutral figure in Study 2. The authors conclude that the bias looks less like active negativity towards higher-weight bodies and more like the absence of the positivity other body shapes receive.

    Where the interpretation runs ahead of the data

    The sample is young, mostly female and German-speaking. Mean self-reported BMI was 22.9 and 22.4, so the samples were centered well below the range the study calls higher weight. How many participants themselves had a higher weight is not reported in the text we read. The authors name this homogeneity as a limit and cite a Paraguayan sample with no implicit weight bias as a reason it matters. The result describes these participants, not people in general.

    The effect is small and the second study is borderline. About 1.3 to 1.7 percentage points in answer probability is what the model implies. Study 2 needed a one-sided test or a different interval type to reach credibility.

    “No drift effect” is not “no perceptual effect”. The drift-rate intervals are wide, especially in Study 2, where they reach from -0.34 to 0.54. A wide interval around zero means the data cannot exclude a difference of either sign. That is our reading; the authors report the intervals correctly and conclude cautiously.

    The model’s labels are an interpretation. The authors state that starting-point biases are usually read as judgment-related, but that manipulations of perceptual encoding can also move starting-point estimates. They do not claim the mapping is proven.

    One task, one picture type. The result comes from an affective-priming-like task with computer-generated figures. The authors explain why the same model does not transfer cleanly to the Implicit Association Test and call their work an initial step. Whether the finding holds in other tasks is untested.

    An implicit measure is not a behavior. The study measures reaction times in a laboratory. It contains no data on hiring, treatment decisions or how anyone treats anyone. The authors link the finding to real-world decisions through earlier research, and that link is theirs, not a result of this paper.

    The training suggestion is untested. The authors propose that anti-bias programs should target pre-existing evaluative tendencies instead of perception, and that depicting higher-weight people in positive contexts could help. Nothing in the two studies tested a training. They themselves note that an earlier attempt to reduce implicit weight bias did not succeed.

    Graphic: dot-and-interval chart of model starting points for intermediate-weight and higher-weight conditions in two studies, with a reference line at 0.5. No people.
    Grafik: Fatosphere Editorial. Quelle: Pollak et al., Sci Rep 2026;16:27408. Gelesen am 17.10.2026.

    How it connects to our other work

    For the evidence on programs that try to reduce weight stigma, see our article on the systematic review of randomized trials. For a small pilot of a training in a clinic, and what it can and cannot show, see our article on weight-inclusive care in primary care.

    Source: Pollak KM, Wachten H, Fenn J, Hartmann R, Meyer-Grant CG, Strahler J, Kiesel A. “Assessing underlying processes of implicit weight bias: a diffusion model analysis.” Scientific Reports 2026;16:27408, doi.org/10.1038/s41598-026-67393-1, PMC13534490. Publication date, authors and license confirmed against the Crossref record. Full text read on 17 October 2026.

  • Weight Stigma Around Conception, Pregnancy and Birth

    Weight Stigma Around Conception, Pregnancy and Birth

    A survey of 511 women in five countries asked who makes them feel judged for their weight while they are trying to conceive, pregnant or after birth. Nearly two thirds said they had experienced weight stigma at least once. The study also reports that internalised weight bias sits between stigma and how women feel about their bodies and themselves. This article reports how the survey was built, what it found and where the paper claims more than its tables show. It does not assess any intervention and does not recommend one.

    The paper is “Exploring the relationships among weight stigma, weight bias internalisation, feeling fat, and self-esteem across preconception, pregnancy, and postpartum” by Michelle Dever, Angela Incollingo Rodriguez, Helen Skouteris and Briony Hill (Melbourne, Worcester Polytechnic Institute in the US, and the University of Warwick in the UK), Health Psychology and Behavioral Medicine, volume 14, article 2635237, published online on 23 February 2026 (doi 10.1080/21642850.2026.2635237). It is open access under a CC BY-NC license. Fatosphere read the full text, but not the supplementary tables. The authors report no competing interests.

    How the survey was built

    This is a cross-sectional online survey, so every woman answered once and nothing is followed over time. In August 2023, 511 women aged 18 to 45 were recruited through a commercial research panel, using quotas and a convenience sample. They had to read English and have internet access. “Preconception” meant actively trying to conceive, and “postpartum” meant having given birth in the past 24 months.

    The sample splits into 216 women in preconception (42.3 percent), 125 pregnant (24.5 percent) and 170 postpartum (33.2 percent). By country: 83 from Australia, 128 from the UK, 121 from the US, 125 from the Philippines and 54 from Singapore. The authors group the first three as “Western” and the last two as “non-Western” for an exploratory comparison. Of the 491 women with a BMI, 23.8 percent were in the obesity category (117 women).

    Weight stigma was measured with a 10-item checklist adapted from the Stigmatising Situations Inventory: for each source (workplace, immediate family, extended family, friends, partners, healthcare, strangers, media, pregnant women or new mothers, society in general), women said yes or no and then how often. The authors reworded the wording for the preconception group and tested it with 10 women. Weight bias internalisation was measured with an 18-item scale (range 18 to 126), “feeling fat” with a 7-item subscale (7 to 35) and self-esteem with the 10-item Rosenberg scale (10 to 40). The analysis used regressions and a mediation procedure with 5,000 bootstrap samples.

    What the survey reports

    How common. 62.6 percent of the women reported weight stigma from at least one source: 62.5 percent in preconception, 59.2 percent in pregnancy and 65.3 percent postpartum. The most often named sources were immediate family (24.3 percent), friends (23.5), extended family (22.1) and the workplace (19.8). Healthcare and partners were each named by 10.6 percent. The authors write that the experiences usually happened a few times a month.

    Where the stages differ. Three sources differed by stage in a chi-square test: the media (16.7 percent preconception, 6.4 pregnant, 10.6 postpartum), other pregnant women or new mothers (12.0, 4.0, 2.9) and society in general (17.1, 4.8, 18.2). Workplace and family did not (p = .391 and p = .150).

    Levels of internalisation. Mean weight bias internalisation was 74.05 (SD 22.37) on the 18 to 126 range, with no significant difference between stages. Feeling fat and self-esteem did differ by stage: the means were 25.10, 22.96 and 25.37 for feeling fat and 25.75, 27.38 and 26.16 for self-esteem (preconception, pregnant, postpartum), so pregnancy had the lowest feeling-fat score and the highest self-esteem. Internalisation correlated with feeling fat at r = .72 and with self-esteem at r = -.57.

    Countries. Women in the two non-Western countries reported more stigma from friends, the workplace, other pregnant women or new mothers and strangers. Women in the three Western countries reported more from healthcare. Effect sizes ranged from 0.01 to 0.43. Internalisation, feeling fat and self-esteem did not differ by country group.

    The mediation result. Across the whole sample, the indirect path through internalisation was significant for workplace stigma and feeling fat (B = 3.35, 95 percent CI 2.37 to 4.36), for family stigma (2.87, CI 2.03 to 3.70) and for media stigma (2.82, CI 1.89 to 3.77). For self-esteem, it was significant for the workplace (-2.48), family (-2.11) and partners (-1.16). In each of the three feeling-fat paths the direct effect was not significant. By stage, the authors name media stigma in preconception, workplace stigma in pregnancy and family stigma postpartum.

    Reading it carefully

    The stage story is not in the prevalence table. The abstract says media stigma was “most prevalent” in preconception, the workplace in pregnancy and family postpartum. In the endorsement table (Table 2), immediate family is named more often than media in preconception (27.8 against 16.7 percent), and in the postpartum group friends (27.1) and extended family (25.9) are named more often than immediate family (24.1). Workplace and family do not differ significantly by stage at all. What the abstract describes is which source was linked to internalisation within each stage in the regressions, and media is the only one of the three with a stage difference in how often it was named. Read the sentence as “linked to”, not “most common”.

    “Across all BMI ranges” is not shown. The discussion says stigma was reported by women of every BMI range. The main text gives the BMI distribution of the sample, but no stigma figures by BMI category. The paper does not tell us how common or how heavy stigma was for women in larger bodies, which is the group this site is about. The abstract of a companion paper (see below) says BMI was not independently related to internalisation, but we did not read that paper.

    Missing BMI and a changing N. Twenty women with biologically implausible BMI values were excluded according to the methods, yet the sample stays at 511 and 491 have a BMI category. The paper does not say how the 20 were handled in the models.

    A mediation model on one time point. The abstract says stigma “promoted” internalisation, which in turn “promoted” feeling fat and lower self-esteem. A cross-sectional design cannot give that order. A woman who already feels fat or has low self-esteem may also notice or report stigma more. The reverse order was not tested. The authors list the cross-sectional design as a limitation.

    The stage samples are small for the stage analyses. The power calculation asked for 477 women for the whole sample. The stage groups have 125 to 216 women, and some stage-by-source cells are very small: only five pregnant women named other pregnant women or new mothers as a source. The stage results name one source per stage, and the full tables are in the supplement, which we did not read.

    Numbers that do not fit. In Table 1 the three non-binary or unsure respondents are shown as 1.5 percent of 511 (they are 0.6 percent). In Table 2, 46 preconception women naming friends is shown as 23.1 percent of 216 (it is 21.3). In the mediation results the direct effect of workplace stigma on self-esteem is B = -5.33 with p = .31, larger than the significant indirect effect of -2.48 but not significant, while a similar family effect of -1.07 has p = .03. We cannot judge whether that is a very wide interval or a typing error.

    “Not only a Western phenomenon” rests on two countries. The paper concludes that the results challenge the idea that body image concerns are mainly Western. That rests on 179 women from the Philippines and Singapore in an English-language online panel. The authors themselves call the cross-country comparison preliminary and the Western/non-Western split broad.

    The authors’ recommendations are untested. The discussion suggests cognitive behavioural approaches, self-compassion and body appreciation practices, screening tools, media-literacy counselling before pregnancy, support for workplace stress and family communication programmes. None was tested in this study. The introduction also lists gestational weight gain above recommendations among outcomes linked to weight stigma and as a risk factor for being stigmatised. We report this as the authors’ framing and do not adopt it. The paper also calls for changes in healthcare, workplaces, media and families, not only individual support.

    A companion paper. The same group published a related analysis in the Journal of Health Psychology on 26 June 2026 (doi 10.1177/13591053261462432). Its abstract reports the same number of women, 511. The publisher’s site did not deliver the full text and we did not use it, so we cannot say how the two papers relate.

    Grafik: Balken zeigen, welchen Anteil der 511 befragten Frauen jede Quelle von Gewichtsstigma nannte, von engster Familie 24,3 Prozent bis andere Schwangere oder Mütter 7,0 Prozent. Keine Personen.
    Grafik: Fatosphere Editorial. Quelle: Dever et al., Health Psychol Behav Med 2026;14:2635237. Gelesen am 14.10.2026.

    How it connects to our other work

    For a mediation model of weight stigma, stress and depression in US adults, with the same cross-sectional limits, see our article on Figueroa and colleagues’ 1,993-adult study. For coping and mental health in 2,632 adults, see our article on Gerend and colleagues. This survey adds the reproductive years and five countries, with the limits above.

    Source: Dever M, Incollingo Rodriguez AC, Skouteris H, Hill B. “Exploring the relationships among weight stigma, weight bias internalisation, feeling fat, and self-esteem across preconception, pregnancy, and postpartum.” Health Psychology and Behavioral Medicine 2026;14:2635237, doi.org/10.1080/21642850.2026.2635237, PMC12931358. Publication date confirmed against the Crossref record. Full text read on 14 October 2026.

  • “They Call Us Cheaters”: Stigma While Taking GLP-1 Drugs

    “They Call Us Cheaters”: Stigma While Taking GLP-1 Drugs

    Most coverage of GLP-1 medications asks whether they work. A communication study published in September 2026 asks something else: what do people say, and not say, to others when they take one? The answer is a small qualitative picture of stigma management, and it contains a finding that matters for anyone who cares about fat stigma. This article reports how the study was built, what the 34 interviewees described, and how far that carries. It does not assess any medication and does not recommend one.

    The paper is “‘They Call Us Cheaters’: Exploring Stigma Management Communication Strategies During GLP-1 Medication Use” by Braidyn Lazenby, Ashley Guidry, Sarah Price and colleagues, Health Communication, published online 18 September 2026 (doi 10.1080/10410236.2026.2734167). Fatosphere read the full text from the publisher PDF. The authors report no conflict of interest and funding from a university research grant (Council on Research and Creativity, First Year Assistant Professor grant).

    How the study was built

    The team interviewed 34 adults over Zoom, 26 women and 8 men aged 21 to 73 (mean 44). Participants were recruited by snowball sampling, which means existing participants brought in further ones. Everyone was taking or had previously taken a GLP-1 medication. The interviews lasted 48 minutes on average and produced 473 pages of transcript. The authors analyzed them with reflexive thematic analysis and read the material through Meisenbach’s 2010 theory of stigma management communication, which sorts responses by whether a person accepts that a stigma applies to them and whether they accept the public’s view of it.

    Bar chart: reasons for starting a GLP-1 medication among 34 interviewees. 16 weight loss only, 13 a health condition plus weight loss, 5 health conditions only.
    Chart: Fatosphere Editorial. Source: Lazenby et al., Health Communication, online 18.09.2026. Read on 11.10.2026.

    Participants differed in why they started:

    Reason for starting, as stated by participantsParticipants
    Weight loss as the only reason16
    A health condition, with weight loss as an additional goal13
    Health conditions only5

    Of the 34, 23 identified as White, 5 as Asian, 3 as Black, and one each as Ashkenazi Jewish, Hispanic and Native American.

    What the interviewees described

    Most participants said they had not been stigmatized to their face. They had overheard or joined conversations in which people on GLP-1 medication were called lazy or described as taking “the easy way out”, and they used those moments to judge who in their circle was safe to tell. One participant kept her use from a close friend who talked badly about coworkers on the drug. The authors report that self-stigma was present in all participants, whatever their reason for starting.

    The authors describe two main strategies.

    Sorting users into an “in” group and an “out” group. Participants separated users with a medical reason, “the right reasons”, from users seeking quick weight loss or an aesthetic result, “the wrong reasons”. The authors stress that this sorting did not follow the reason people gave when asked: several participants who named weight loss as their only reason still pointed to blood pressure, sleep apnea or prediabetes when describing themselves to others. Some showed medical records to others, one participant her blood work to her father. Others set themselves apart by pace: one participant said she “did it slowly” and “like how I should”. The authors read this as a move that protects the individual and, at the same time, confirms the public view that weight loss alone is a bad reason.

    Stressing effort. Participants described the decision as a last resort after years of struggle, and described the medication as a tool next to their own work, not a shortcut. The quote that gives the paper its title comes from a participant who said “They call us cheaters” and then listed portion control and exercise.

    The finding that matters most for this site

    The authors argue that people on these medications face a “weight-bias paradox”: weight loss is rewarded through fat stigma, while the method is devalued. Their interviews add a third layer. Wanting to lose weight at all was itself stigmatized, and participants managed this by hiding the wish. One participant described having to forgive herself for feeling good about the weight she lost, although she had not started for weight loss.

    The authors also say the strategies feed the stigma they respond to: hiding a weight loss goal and treating open users as “others” shifts blame onto people who show no effort or no medical reason. That is their interpretation of interview material. It is not a measured effect.

    Reading it carefully

    Interviews describe talk, not outcomes. The abstract calls the strategies “effective for stigma management”. The paper has no outcome measure, no comparison group and no follow-up, so we find nothing in it that tests effectiveness. It describes what people said they do.

    The sample is small, recruited through networks, and mostly White and female. The authors say so and expect Black, Indigenous and other people of color to experience stigma differently. Only 5 participants had medical reasons alone, so statements about that group rest on very few people.

    The text gives no counts per theme. It does not say how many of the 34 used each strategy, so readers cannot tell whether a quoted case is typical.

    An inconsistency in the methods. The paper reports 34 participants and 34 interviews, and also that one interview included two participants. Both cannot hold. It is probably a small slip, but we could not resolve it from the text.

    Some claims are cited, not found. The statement that stigmatizing language accounts for as much as half of GLP-1 discussion on Twitter comes from an earlier study (Haggerty and colleagues, 2023), and we have not checked it.

    One authors’ point is untested here. In the implications, the authors say body positivity and body neutrality, while promising for health outcomes, can at times invalidate people who want to lose weight, and cite a 2022 paper for this. The interviews do not test it. We report it because it concerns this site’s field, and because it is a view the movement should be able to look at.

    A note on weight-loss framing

    Several quotes include participants’ own ideas about how weight loss should be done. We report them as stigma management speech, not as advice. The paper itself says medical uses described by participants are not medical advice. This article takes no position on treatment.

    Why it belongs here

    The study shows how stigma spreads sideways: people who are stigmatized for one thing protect themselves by pointing at others. That mechanism is old and well known in stigma research, and the interviews show it in a new setting. For related work on the same medications, see our article on a randomized experiment on how people are judged after weight loss on a GLP-1 and after regain, which the Lazenby team cites for the stigma attached to weight regain after stopping.

    Source: Lazenby B, Guidry A, Price S, Shuvo MSM, Alikhanova T, Morrison C, Davis N, Lenard M. “‘They Call Us Cheaters’: Exploring Stigma Management Communication Strategies During GLP-1 Medication Use.” Health Communication, online 18 September 2026, doi.org/10.1080/10410236.2026.2734167. Publication date confirmed against the Crossref record. Full text read on 11 October 2026.

  • Weight Stigma, Depression and the Role of Stress

    Weight Stigma, Depression and the Role of Stress

    Weight stigma goes with more depressive and anxiety symptoms. A 2025 US survey of 1,993 adults asks how: does perceived stress sit in between? The authors find that it carries about 37 to 38 percent of the statistical link. The study is cross-sectional, so “carries” describes a model, not an observed sequence of events.

    The paper is “Weight stigma and mental health symptoms: mediation by perceived stress” by David G. Figueroa, William D. Murley, Jordan E. Parker, Jeffrey M. Hunger and A. Janet Tomiyama (UCLA and Miami University), a Brief Research Report published on 2 July 2025 in Frontiers in Psychiatry (open access). The authors state that the study was preregistered.

    How the data were collected

    An online survey ran on Qualtrics between December 2019 and January 2020. Recruitment used quotas matched to US Census benchmarks for age, gender, race and ethnicity, income and region. Of 2,022 respondents, 1,993 remained after exclusions: failed attention checks, implausible height or weight, or a BMI below 12 or above 70. Mean age was 47.2 years (SD 17.3), 51 percent women, 63 percent White, 15.5 percent Hispanic or Latino, 13 percent Black or African American.

    Chart: mediation paths from weight stigma via perceived stress to depressive and anxiety symptoms (Figueroa et al. 2025, Table 3)
    Chart: Fatosphere Editorial. Source: Figueroa et al., Front Psychiatry 2025;16:1587105, Tabelle 3. Read on 07.10.2026.

    Weight stigma was measured with two single items, averaged: how often respondents were treated with less respect, harassed or discriminated against because of their weight (experienced), and how often they worried about being stereotyped or mistreated because of their weight (anticipated). Both used a 4-point scale from “not at all” to “often”. Perceived stress came from a 4-item version of the Perceived Stress Scale (past month, 5-point scale). Depressive and anxiety symptoms came from 4-item PROMIS short forms (past seven days). Missing data (up to 11.8 percent per variable) were handled with Bayesian multiple imputation. Age, BMI, region, gender, income, education and race and ethnicity were covariates.

    The results

    Weight stigma was linked to more stress, depression and anxiety. Partial correlations (age, BMI and income held constant, non-imputed data): weight stigma with perceived stress .25, with depressive symptoms .38, with anxiety symptoms .37. Perceived stress correlated .66 with depressive and .62 with anxiety symptoms.

    Stress accounted for about 37 to 38 percent of the link. The table shows the two mediation models as reported (unstandardised coefficients, 95 percent credible intervals in brackets).

    PathDepressive symptomsAnxiety symptoms
    Stigma to stress (a)0.24 (0.20 to 0.29)0.24 (0.20 to 0.29)
    Stress to symptoms (b)0.79 (0.75 to 0.84)0.70 (0.65 to 0.74)
    Indirect effect0.19 (0.16 to 0.23)0.17 (0.14 to 0.20)
    Direct effect (c’)0.31 (0.26 to 0.35)0.29 (0.25 to 0.34)
    Total effect (c)0.50 (0.44 to 0.56)0.46 (0.41 to 0.52)
    Share mediated38 percent37 percent

    I checked the arithmetic: 0.24 times 0.79 gives 0.19, 0.24 times 0.70 gives 0.17, and 0.19 divided by 0.50 and 0.17 divided by 0.46 give the stated shares. The authors call the indirect effect small by Cohen’s benchmark (υ = .02).

    Both direct effects stayed after adjusting for BMI. The authors read this as weight stigma being more than a marker of body size. In an exploratory regression, younger age and higher BMI went with more reported stigma, and Hispanic or Latino and Asian respondents reported less than Black respondents (the reference group).

    Reading it carefully

    The design cannot order the variables. The authors say so: no causal conclusions are possible, and a mediation model across one time point needs a compelling case for the order. They argue from other, experimental work that stigma raises stress and stress raises symptoms, and call their result preliminary. In my reading, the data alone would fit other orders as well, for example people with more depressive symptoms reporting more stress and more stigma. The paper does not test that reversed model.

    Stress and anxiety are measured close together. One of the stress items reads “How often have you felt nervous and stressed?” and an example item of the anxiety scale reads “I found it hard to focus on anything other than my anxiety”. The b path for anxiety (0.70) and the correlation of .62 are large. In my reading, content overlap between the two scales can inflate the mediated share. That is my observation, not the authors’.

    “Weight stigma” here is two single items. The composite mixes experienced stigma with worry about future stigma, and each is one question. The authors cite earlier work showing it correlates with validated questionnaires, but that is a different publication on the same dataset. Mental health was also measured with brief 4-item forms, and everything is self-report. The authors name both limits.

    The data are from before 2020 and were used before. Collection ended in January 2020, before the pandemic. The covariates were chosen based on earlier work with the same dataset, so this is a preregistered analysis of existing data, not a fresh sample.

    Quota sampling is not random sampling. The discussion says the census-matched sample gives “high generalizability” to the US population. Quotas match margins such as age and income, and the text I read mentions no reweighting after the exclusions. I would read that claim as plausible, not shown. The text I read does not report the BMI distribution of the sample, so how many respondents were in larger bodies is unknown.

    Framing. The paper builds on the COBWEBS model, which proposes that stigma-related stress leads to weight gain through eating and cortisol. This study measures none of that, and I report the framing, not the claim. The authors conclude that stress-reduction strategies may be needed in interventions “if replicated”, and mention mindfulness work as promising, citing other studies. No intervention was tested here, and this article does not evaluate any treatment or programme.

    The authors report no conflicts of interest and funding from the National Science Foundation and the NIH. They state that no generative AI was used.

    Why it belongs here

    The study tests a mechanism, not an outcome rate: stigma as a stressor. That fits a plain reading of the data. Being treated badly, or expecting to be, goes with feeling more stressed, and stress goes with more symptoms. Whether it works in that order, in people in larger bodies specifically, needs longitudinal data. For related studies in this series see the Gerend survey on coping and depression in 2,632 adults, which asks what may buffer the link, and the Hong Kong longitudinal study, which follows people over time and finds no vicious cycle. The survey is US-only and says nothing about Germany or the UK.

    Source: Figueroa DG, Murley WD, Parker JE, Hunger JM, Tomiyama AJ. “Weight stigma and mental health symptoms: mediation by perceived stress.” Frontiers in Psychiatry 2025;16:1587105, published 2 July 2025, doi.org/10.3389/fpsyt.2025.1587105. Full text read on 7 October 2026.

  • Who Reports What: Weight Stigma Across Hispanic, White and Black Adults in Two US Clinics

    Who Reports What: Weight Stigma Across Hispanic, White and Black Adults in Two US Clinics

    A common assumption is that weight stigma works the same way for everyone. A new US survey of 296 adults with a BMI of 30 or higher suggests that three different things, prejudice, experienced stigma and internalised stigma, can point in different directions across groups. The study is small, drawn from two clinics, and cannot say why the groups differ. What it offers is a measured comparison, with limits the authors name and some the text leaves open.

    The paper is “Weight stigma among diverse ethnic groups with obesity in the U.S.: the USA-OBESTIGMA study” by Rodolfo J. Galindo, Giuliana Arevalo, Albert Lecube, Guillermo E. Umpierrez and colleagues, published on 14 February 2026 in the International Journal of Obesity (open access). The paper uses the term “obesity” for people with a BMI of 30 or higher; I use it where I describe the study.

    How the data were collected

    Between December 2022 and March 2024, patients at two academic outpatient clinics, one in Atlanta (Grady Memorial Hospital, Emory University) and one in Miami (University of Miami), filled in three questionnaires on the same day. Adults with a BMI of 30 or higher were eligible. Of 422 people contacted, 122 declined and 4 were excluded, which leaves 296.

    Bar chart: mean scores on three scales by group in the USA-OBESTIGMA study (n = 296).
    Bild: KI-generiert (Gemini) · Image: AI-generated (Gemini)

    The sample: mean age about 55, 59 percent women, mean BMI 36.7. By self-reported group, 123 were Hispanic (42 percent), 68 non-Hispanic White (23 percent) and 105 non-Hispanic Black (35 percent). The study is part of an initiative of the Spanish Society for the Study of Obesity that runs similar surveys in several countries.

    The three instruments measure different things. The Anti-Fat Attitudes scale (AFA, 0 to 9) measures prejudice against people with obesity. The Brief Stigmatizing Situations Inventory (SSI-B, 0 to 9) measures how often someone has lived through stigmatising situations. The Weight Bias Internalization Scale (WBIS, 7-point) measures how far someone has taken on negative stereotypes about their own body.

    The results

    Group averages differ on every scale, and the group with the highest score is not the same on each. The table shows the means as the paper’s text reports them.

    ScaleHispanicNon-Hispanic WhiteNon-Hispanic Black
    Anti-fat attitudes (AFA)3.553.292.12
    Stigmatising experiences (SSI-B)1.242.011.21
    Weight bias internalisation (WBIS)2.692.962.27

    All three comparisons are reported as statistically significant (p < 0.001 for AFA and SSI-B, p = 0.0006 for WBIS).

    Adjusted for age, sex, income, education and BMI, some differences hold and some do not. For anti-fat attitudes, Black participants scored lower than Hispanic participants (β = -1.385, p < 0.001), while White and Hispanic participants did not differ significantly. For stigmatising experiences, White participants scored higher than Hispanic participants (β = 0.894, p < 0.001), while Black and Hispanic participants did not differ. For internalisation, Black participants scored lower than Hispanic participants (β = -0.626, p < 0.001), and the gap between White and Hispanic participants was borderline (p = 0.055).

    Most people with a BMI of 30 or higher did not call themselves obese. Between 69 and 73 percent in each group described themselves as having overweight, and 19 to 29 percent as having obesity. The authors call this a misperception. That is one reading; it also shows that a BMI cut-off and how people describe their own bodies are not the same thing.

    Doctors recommending a diet was the most common stigmatising experience in all three groups. The paper reports it for 94.1 percent of White, 83.8 percent of Hispanic and 81.0 percent of Black participants (p = 0.01), including when the person had not come to talk about weight. This is the one item-level figure I use; see the next section for why.

    Younger participants reported more stigmatising experiences, and so did those with less than a high school education compared with a graduate degree. The authors link the age finding to earlier studies in which people who developed severe obesity before 18 reported more severe stigma.

    Reading it carefully

    This is a cross-sectional survey, not an explanation. It shows that group averages differ. It does not show why. The explanations in the discussion, such as different cultural norms around body size, are plausible and untested here. The authors also call higher BMI “a coping mechanism or resilience” as a possible reason for the negative link between BMI and anti-fat attitudes; the study did not measure that.

    The sample is small and regional. 296 people from two cities, with a large Hispanic share because of Miami. The authors say the results may not generalise to the US. The groups were recruited in clinics, so they are people who use specialist care, and 122 of 422 people contacted declined. The groups are also unequal in size, with 68 White participants against 123 Hispanic.

    Some numbers in the text do not add up, so I leave them out. Several different SSI-B items are reported with identical percentages for the same group: 77.94 percent for White participants on two different items, and 31.14 percent for Hispanic participants on the same two items. Either the items happen to match or something went wrong in the table or text. Tables 1 to 4 are not readable as text in the full text, so I could not check them. For the age effect the text gives β = -0.19 with a standard error of 0.006 and p = 0.024; those three values are not consistent with each other, so I report only the direction. The abstract gives a mean age of 54.9, the text 54.8.

    The paper frames weight as a medical problem; I report its findings, not that frame. The discussion describes obesity as “a chronic metabolic disease” and says internalised stigma can drive weight gain. The study did not test either. The authors call for education programmes against weight bias; I report that as their recommendation, not as a finding.

    Conflicts of interest. The paper’s funding is internal to the University of Miami. The first author discloses research support from and consulting for several drug and device companies, including Novo Nordisk and Eli Lilly, outside this work. That is worth knowing, not a finding against the paper.

    This article reports how one survey measured and compared weight stigma. It does not evaluate any treatment or weight-related intervention.

    Why it belongs here

    Stigma research in the US is often drawn from White samples, and the authors say so. This study compares three groups side by side and shows that “experienced”, “held” and “internalised” stigma are separate measurements that do not move together. The doctor-recommends-a-diet figure, 81 to 94 percent across groups, is the part that needs the fewest caveats. For earlier studies in this series see our article on the cultural value of fat in the US, Portugal and Mexico and the Hong Kong longitudinal study. For Germany and the UK this survey does not speak: it is US-only.

    Source: Galindo RJ, Arevalo G, Zabala Z, Flores I, Soliman D, Moazzami B, Rashied A, Lecube A, Umpierrez GE. “Weight stigma among diverse ethnic groups with obesity in the U.S.: the USA-OBESTIGMA study.” International Journal of Obesity 2026;50:1027-1034, published 14 February 2026, doi.org/10.1038/s41366-026-02028-z. Full text read on 4 October 2026.

  • Weight Stigma in Three Countries: What 1,865 Adults Who See Themselves as Overweight Reported

    Weight Stigma in Three Countries: What 1,865 Adults Who See Themselves as Overweight Reported

    A study published on 20 August 2026 surveyed 1,865 adults in the United States, Portugal and Mexico who described themselves as overweight. It asked two different questions: how much weight discrimination they personally experience, and how negatively they think their culture views fat. The two turned out to behave differently, and only one of them varied by country in the way the authors expected.

    The paper, “Weight discrimination and the negative cultural value of fat: the relationship to well-being across individuals with higher weights of different nations”, is by Ana Clara Vieira Zaidan and Joseph D. Wellman of the University of Mississippi. It appeared in the International Journal of Obesity (open access). The authors say that, to their knowledge, no earlier weight stigma study had asked people in larger bodies how they perceive their own culture’s attitude toward fat.

    Who took part

    Participants were recruited separately in each country through the online platform Prolific: 676 from the United States, 616 from Portugal and 573 from Mexico. To qualify, they had to agree with the statement “I consider myself to be overweight” with a 5 or higher on a 7-point scale. The authors chose self-perception over BMI because they cite research finding it more predictive of negative outcomes. Participants also had to be native to and living in their country and fluent in English, because the survey was in English.

    Of 1,969 people who completed the survey, 104 were excluded for missing data or failed attention checks, leaving 1,865 (934 women, 931 men, mean age 34.6). The three samples differ in composition. The US sample was 78.8 percent White, the Portuguese sample 95.3 percent White, and the Mexican sample 53.2 percent Latine. The countries also differed significantly in age, so age was controlled in the analyses.

    What was measured

    Perceived weight discrimination came from 7 items such as “I experience discrimination because of my weight”, rated 1 to 7. The negative cultural value of fat came from just two items, “In my culture, being fat is considered a bad thing” and “In my culture, being thin is an important part of being attractive”, also rated 1 to 7. Psychological distress was the DASS-21 (depression, anxiety and stress, 21 items scored 0 to 3 and summed), and difficulties in emotion regulation came from the 16-item DERS-16.

    The two stigma measures correlate at r = 0.31, which the authors take as evidence that they capture different things: your own experience versus your read of the culture around you.

    The findings

    Discrimination. Women reported more perceived weight discrimination than men in all three countries. Portuguese participants reported more than American participants (a difference of 0.26 points on the 7-point scale) and more than Mexican participants (0.40). American and Mexican participants did not differ significantly. The gender gap did not differ significantly between countries.

    Cultural value of fat. Here the gender gap did depend on the country. Portuguese women scored 0.93 points higher than Portuguese men, Mexican women 0.61 points higher than Mexican men. Among Americans the difference was 0.13 points and not significant.

    Well-being. Women reported higher psychological distress and more difficulty with emotion regulation than men. Participants from the United States reported lower distress, by about three points on the summed DASS-21 (which runs from 0 to 63), than both Portuguese and Mexican participants, and fewer emotion regulation difficulties. Portugal and Mexico did not differ from each other.

    The mediation models. The authors tested whether the gender differences in well-being could be statistically accounted for by the two stigma measures, with nationality allowed to change the pattern. Perceived discrimination did so in all three countries, most strongly in Portugal. The negative cultural value of fat did so only for Portuguese and Mexican participants, not for Americans. The full estimates are in Table 3 of the paper.

    Reading it carefully

    The headline hypothesis was that gender gaps in perceived discrimination would be larger in Portugal and Mexico than in the United States. That was not supported: there was no significant gender-by-country interaction for discrimination. Only the cultural-value measure showed the predicted pattern. The abstract’s sentence that cultural context moderates the associations is therefore true for that measure, not for everything.

    “Mediation” here is a statistical term. The data are a one-time online survey, so the study cannot say that perceiving a hostile culture causes distress, or the other way round. All measures are self-reports. The cultural-value measure has two items. The survey was in English, and the authors themselves note that in Portugal and Mexico this may have selected more acculturated participants or primed answers toward US norms. Online recruitment leaves out people without internet access. The sample is people who call themselves overweight, so it says little about people in larger bodies who do not use that word for themselves.

    A smaller point: a few degrees-of-freedom figures in the results text, for example a three-group comparison reported with one numerator degree of freedom, look like typos. The F values and effect sizes are internally consistent enough that this does not change the findings, but this article does not quote those figures.

    This article reports the design and findings of one study. It does not evaluate any treatment or weight-related intervention.

    Why it belongs here

    Discussions of weight stigma often treat it as one thing. This paper separates what happens to you from what you believe your culture thinks, and finds that the second is where the countries and the genders pull apart. It also finds the United States had the lowest distress of the three samples, which is not what a simple “more stigma, more harm” story would predict, and the study is not built to explain it.

    Germany and the United Kingdom are not covered by this data.

    Source: Vieira Zaidan AC, Wellman JD. “Weight discrimination and the negative cultural value of fat: the relationship to well-being across individuals with higher weights of different nations.” International Journal of Obesity 2026, doi.org/10.1038/s41366-026-02192-2. Full text read on 1 October 2026.

  • Novo Nordisk Didn’t Lose Its Canadian Patent. It Forgot to Pay For It.

    Novo Nordisk Didn’t Lose Its Canadian Patent. It Forgot to Pay For It.

    On 29 June 2026, Health Canada approved Sevmia, a generic semaglutide made by the Canadian company Apotex, specifically for chronic weight management in patients 12 and older. It is a routine-sounding regulatory notice. It also quietly answers a question this magazine raised in July: is the multi-year wait for cheap semaglutide a fact of chemistry and law, or an accident of one country’s patent office?

    To be clear about what this article is not: it is not an argument for or against taking semaglutide, and it says nothing about dose, effectiveness, or side effects. That is between a patient and their doctor. What it is about is a policy story about who gets to pay less for the same molecule, and why.

    Canada now has three approved generics

    Sevmia is the third generic semaglutide product Health Canada has cleared, and the first approved specifically for weight management rather than diabetes. The sequence: Dr. Reddy’s Laboratories received approval on 29 April 2026 for a diabetes-indication generic in 2mg and 4mg pens; Apotex followed on 1 May 2026 with its own diabetes-indication version; Apotex’s Sevmia, cleared 29 June 2026, is the first with a weight-management label. Health Canada says six more generic semaglutide submissions were still under review as of that date. Canada became, by its own regulator’s account, the first G7 country to approve a generic semaglutide product at all, when the Dr. Reddy’s approval landed in late April.

    Health Canada’s language on why it approved the drugs is procedural, not political: authorization followed, in the agency’s words, “a thorough review of evidence provided by the company” showing the drug “meets Health Canada’s criteria for safety, efficacy and quality.” Nothing in the public record ties the approval to a policy decision about price. What changed was that a patent that used to block generic competition no longer exists in Canada, and it stopped existing years before anyone planned for that to happen.

    The price gap, in the same currency the drugs are actually sold in

    Brand-name Ozempic and Wegovy in Canada run to more than 450 Canadian dollars a month, according to pharmacy-chain reporting from May 2026. Apotex told reporters at the time that its generic would sell for roughly a third of that brand price. Health Canada’s own general guidance is that generic drugs in the country typically cost 45 to 90 percent less than the brand name.

    Compare that with what Novo Nordisk itself lists for the same drugs in the United States, on its NovoCare pricing page: Ozempic at roughly 1,028 US dollars a month, Wegovy at roughly 1,350 US dollars a month. That is not the price after a rebate or a pharmacy benefit manager’s cut, it is the list price the company sets. Converted or not, it is several times the Canadian brand price, before anyone gets near a Canadian generic.

    Fatosphere reported in July, in “Fat and Poor: The GLP-1 Access Gap Punishes Twice,” that US patents on semaglutide don’t begin to expire until 2032, and concluded there would be “no cheap legal version for years.” That remains true for the United States specifically. It was never true everywhere, and Canada is the proof.

    Why Canada, and why by accident

    The Canadian patent that would have blocked generic semaglutide, CA 2,601,784 (“Acylated GLP-1 Compounds”), did not expire on schedule. It lapsed because a maintenance fee, a routine annual payment of 250 Canadian dollars, rising to 450 dollars with a late penalty, went unpaid. The last payment on record was made on 23 October 2018. Canadian patent law gives a lapsed patent a “period of reversal” during which the fee can still be paid to bring it back to life. That window closed on 31 August 2020. After that date, the patent was gone for good, more than a decade before Novo Nordisk’s active-ingredient protection would otherwise run out in the US (2032) or the EU and Japan (2031).

    Novo Nordisk has since described the missed payment as a strategic choice rather than an oversight. The documented paper trail, a specific fee amount, a specific missed date, a specific expired deadline for reinstatement, is the part that is independently verifiable. The company’s own retrospective framing of why it let that deadline pass is the company’s account of its own decision, made after the fact, and this article treats it as exactly that: their characterization, not an independently confirmed motive.

    One caveat worth keeping in view: a separate Certificate of Supplementary Protection tied to the drug’s device or formulation has a listed expiry date of 20 March 2026, with a term that can extend to 20 March 2028. That is a narrower, different kind of protection than the base compound patent that lapsed in 2020, and it is one reason regulatory and commercial clarity in Canada is still settling even as three generic products are already approved.

    What this does and doesn’t prove

    It proves that the timeline Fatosphere described in July, patents holding until the early 2030s, therefore no affordable legal semaglutide until then, was a description of the United States, not of pharmaceutical patent law as such. A single missed payment in one country changed that country’s timeline by more than a decade. Nothing about the drug, the science, or global patent treaties required that outcome; a filing office in Ottawa and a calendar did.

    It does not prove that Canada’s accident will repeat itself anywhere else. Germany’s and the rest of the EU’s active-ingredient patents are separately filed and, per current reporting, run to 2031 regardless of what happened in Canada; Fatosphere has already covered how France and Germany diverge on reimbursing semaglutide even before patents are the issue (see “Covered in France, ‘Lifestyle’ in Germany”). Canadian generic supply is also not yet evenly available: the pharmaceutical supply-chain group Vital told reporters in May that availability “may vary across regions as products move through the supply chain,” and Sevmia’s weight-management approval is only weeks old as this goes to press.

    And it says nothing about whether cheaper access changes the underlying stigma this magazine covers elsewhere: who gets treated as making a legitimate medical choice, who gets treated as having cheated, and whether a lower price tag closes that gap or just moves it. That is a different question, and one Canada’s patent office did not answer.

    What this piece is not

    This is a report on patent history and drug pricing, not medical or financial advice, and not a recommendation for or against taking semaglutide. It makes no claim about dosing, effectiveness, or safety, and no before-and-after comparison of any kind. Canadian prices and availability described here should not be assumed to apply outside Canada, and nothing here should be read as advice to import or order medication across borders.

    Sources: Health Canada news release, “Third generic semaglutide product approved for weight management,” 29 June 2026; Pearce IP, “First Generic Ozempic® (Semaglutide) Approved in Canada for Dr Reddy’s & Apotex,” 29 April 2026; Global News, reporting on generic semaglutide reaching Canadian pharmacies, May 2026; Drug Discovery Trends, “Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CA$250 patent”; GoodRx, Wegovy and Ozempic cost overview citing Novo Nordisk NovoCare list prices, 2026; Fatosphere, “Fat and Poor: The GLP-1 Access Gap Punishes Twice,” July 2026. Read 27 September 2026.

  • Protection Only If You’re Sick Enough

    Protection Only If You’re Sick Enough

    Germany’s General Equal Treatment Act (AGG) lists eight protected characteristics: race, ethnic origin, sex, religion, disability, age, sexual identity, and belief. Body weight is not one of them. Someone who is passed over for a job, denied a promotion, or fired because of their weight generally has no claim under German anti-discrimination law.

    There is one route in anyway, and it runs through the characteristic of disability. It is real, but it is narrow, and it opens only at a point most people who experience weight discrimination never reach: a documented medical file.

    The case that opened the door

    Karsten Kaltoft worked for about 15 years as a childminder for the municipality of Billund, Denmark. He was obese throughout his employment. In 2010, the municipality laid him off as part of a staff reduction in which he was the only one of 94 childminders dismissed. The exact reasons for the dismissal were disputed; what was undisputed was that his weight had come up repeatedly during his employment, including during an unannounced home visit. Kaltoft, represented by his union FOA, sued the municipal employers’ association Kommunernes Landsforening (KL), arguing the dismissal amounted to discrimination on the basis of his obesity. The Danish court referred two questions to the European Court of Justice: whether obesity is itself a prohibited ground of discrimination under EU law, and whether it can fall under the disability protections of Directive 2000/78/EC.

    The CJEU ruled on 18 December 2014 (Case C-354/13) with a two-part answer. There is no general EU-law prohibition on discrimination based on obesity as such. But obesity can fall within the concept of disability where it “entails a limitation which results in particular from long-term physical, mental or psychological impairments which, in interaction with various barriers, may hinder the full and effective participation of the person concerned in professional life on an equal basis with other workers.” Whether that threshold was met in Kaltoft’s own case was left to the national court to decide, not the CJEU itself. The Danish court later found that his obesity did not meet it, and dismissed his claim.

    What a German court did with that test

    Two years later, a German court had to answer the same question. The Regional Labour Court of Lower Saxony (LAG Niedersachsen) ruled on 29 November 2016 (case 10 Sa 216/16) on a fixed-term truck driver with grade III obesity, a BMI above 40. His employer had declined to renew his fixed-term contract after two years, despite good performance and unremarkable occupational health checks, citing possible medium-term health risks. The driver argued this was disability discrimination.

    The court applied the CJEU’s test word for word, and still ruled against him. Severe obesity as such, it held, does not constitute a disability under sections 1 and 7(1) of the AGG and the underlying EU law. Each case requires a separate, individual assessment of whether the person actually has restricted mobility or a condition that impedes the job in question, and the burden of proving that lies with the person claiming discrimination. A mere prediction of future health risk is not enough, however plausible it sounds. In this case, the driver could not point to a documented mobility restriction or a diagnosed condition that had actually interfered with his work as a driver.

    What this means in practice

    Read together, the two rulings draw a clear, if inconvenient, line. The disability category does not protect fat bodies; it protects the documented, lasting functional limitation that a fat body may or may not come with. Someone treated worse because they are fat, without a doctor having established and being able to prove such a limitation, has no access to the AGG through this route. The bar is not “obese.” It is “obese, and provably restricted in a way that meets the AGG’s disability standard.” That is a considerably narrower door than the public debate about “obesity as a disability” often implies.

    That also explains why this legal route is barely visible in German practice. Using it means producing a medical certificate for a functional limitation and proving it in court, while the discrimination people actually experience day to day usually looks nothing like that: the dismissive comment, the passed-over application, the office chair that doesn’t fit. None of that has a foothold in the AGG as it currently stands, certificate or not.

    The Gesellschaft gegen Gewichtsdiskriminierung e.V. (Society Against Weight Discrimination), Germany’s advocacy group on this issue, has long called for adding body weight directly to Section 1 of the AGG, rather than routing it through disability. Until that happens, the path through Kaltoft and its German application remains the only judicially confirmed option, and it is open only to people who can prove an impairment, not to people who are simply discriminated against.

    What this piece is not

    This is a report on the state of the law, not legal advice. Whether a claim exists in any individual case depends on the specific facts and is a question for a lawyer, not an article. Both rulings cited here explicitly require an individual, case-by-case assessment; nothing here substitutes for one.

    Sources: CJEU, judgment of 18 December 2014, Case C-354/13 (FOA v Kommunernes Landsforening); LAG Niedersachsen, judgment of 29 November 2016, case 10 Sa 216/16; Gesellschaft gegen Gewichtsdiskriminierung e.V.. Read 26 September 2026.